So what's your target? And the only reason I ask, is because the May $2 calls are $1.70. Buy 20 of those for $3400. If it goes back to $5 by then you make 75%. That beats the hell out of these little 5% gains you crow about on days when every toilet stock in the world is up that much.
This is a crazy story and an example of how things can go from zero to sixty. Say they pulled off this scheme and the US sees the helicopter heading to a Chinese ship do they destroy it with a missal as it lands... these type of small affairs can start wars.
Can we save the off-topic posts for after hours? It dilutes the thread. Watch the Q's drop on the jobs and retail sales report in two minutes. They're at $405.
Ya know the P/C ratio on that thing has been off the charts now for well over a week. Don't underestimate Mr Rily himself. I suspect he has the contacts to engineer this thing right back to $30 just out of spite. No way I'd short that stock. You watch... he'll make sure every one of those puts expires worthless. Hell, he's probably the one selling them so he can use the funds to walk the stock up while the DOM is low on the sell side.
THE INCOME INVESTOR Top Dividend Stock AbbVie Runs Hot As Market Approves Of Acquisition Spree Shares of STOCK OF THE WEEK biotech AbbVie(ABBV) are hot. The stock is nearing a buy point, having risen for 11 consecutive days — the longest streak since December 2021.- The Chicago-based company — best known for its rheumatoid arthritis drug Humira — has been busy. On Nov. 30, it announced the acquisition of cancer-drug maker ImmunoGen(IMGN) for $10.1 billion. Only a week later, on Dec. 6, AbbVie announced yet another acquisition, this time of neuroscience company Cerevel Therapeutics(CERE) for $8.7 billion. Market historians may need to chime in on the last time a company has seen such a run while also announcing multiple acquisitions. Despite offering a 95% premium to ImmunoGen's stock price, AbbVie shares were still higher on the announced acquisition, highlighting confidence in management's ability to find and unlock shareholder value. Dividend Stock Offers Yield In Biotech Sector For investors chasing income, AbbVie fits the bill, boasting a 4% annualized dividend yield. This is particularly high for the biotech sector which often offers investors little to no yield. AbbVie has increased its dividend for 10 straight years, which amounts to every year since its 2013 spinoff from Abbott Laboratories(ABT). The dividend will be once again increased in 2024, this time to $1.55 quarterly, with the next dividend to trade with an ex-dividend date of Jan. 12. As previously highlighted in this column in August, AbbVie continues to represent a strong choice for conservative investors looking for yield in the biotech sector. With a pipeline of essential drugs, AbbVie also offers security lacking in many other biotech names. Recent acquisitions, while adding debt, have also allowed AbbVie to diversify further away from its flagship drug Humira. Investors can take security in debt rated at a strong BBB+ by S&P Global. Shares of AbbVie are forming a cup pattern while quickly approaching a 154.88 buy point //
I listened to a couple of short presentations yesterday to counter the company’s. They’re going to have to dilute, something ugly is up. I dumped my shares because the puts keep flowing.
Can we save the off-topic posts for after hours? NO. WHEN I TALK TO HEDGE FUND MANAGERS ABOUT THEIR RED ALERT FEARS- MANY TELL ME WAR OF TAIWAN. WE SIMPLY CANNOT LET CHINA HAVE ALL OF THAT TECH. WE COULD BE AT WAR RIGHT NOW IF THIS PLAN HAD GONE SIDEWAYS. ALWAYS VIEW THE WORLD IN AN INVESTMENT PRISM.- STONEY
He has some credible followers like Andrew Left, Mark Cuban and my favorite kid friendly journalist Coffeezilla. https://twitter.com/AlderLaneEggs?r...io/iframe/twitter.min.html1735020600262021627
That has nothing to do with a Youtube video of a Chinese missile. You can talk geopolitics AS THEY APPLY TO THE MARKET all day long... silly Youtubes have nothing to do with anything.